Compare Medtronic PLC (MDT) vs Oscar Health Inc (OSCR) Price & Performance

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.

Oscar Health (OSCR) trades at $29.60, up 1.72% today, showing mixed signals with a bullish technical trend but bearish oscillators. The company reported revenue growth to $11.70B in 2025, though net income remains negative at -$443.15M. Recent earnings beat expectations in Q1 2026 with EPS of $2.07, while analyst sentiment is divided with a consensus price target of $24.67. Positive cash flow trends and media coverage highlight growth potential amid ongoing profitability challenges.

Outlook: OSCR offers growth exposure in health insurance with strong revenue expansion and cash flow, but profitability risks persist. Investment opportunity lies in execution toward breakeven, while risks include margin pressure and competitive threats. The stock's current price above consensus target suggests cautious optimism is warranted.